Navigation Links
Harvard Stem Cell researchers create cells that line blood vessels
Date:8/22/2013

In a scientific first, Harvard Stem Cell Institute scientists have successfully grown the cells that line the blood vesselscalled vascular endothelial cellsfrom human induced pluripotent stem cells (iPSCs), revealing new details about how these cells function. Using a unique approach, the researchers induced the differentiation of specific cell types by generating mechanical forces on the surface of the iPSC-derived endothelium mimicking the flow of blood. For example, cells that felt a stronger "flow" became artery cells, while those that felt a weaker "flow" became vein cells.

"It was especially exciting to us to discover that these cells are basically responding to biomechanical cues," research leader Guillermo Garca-Cardena, PhD, an HSCI Affiliated Faculty member, said. "By exposing cells to 'atheroprone flow,' we can direct differentiation of these cells into cells that are present in areas of the circulatory system that we know are affected by diseases like atherosclerosis." Garca-Cardena is now working on modeling the formation of arterial plaques using human iPSC-derived vascular endothelial cells and identifying potential drugs that might prevent plaque formation.

Garca-Cardena's team, which included Harvard School of Engineering and Applied Sciences graduate student William Adams, found that the iPS-derived human endothelial cells display three critical functions carried out by mature endothelium in the body: mounting inflammatory responses, keeping blood from leaking out of the blood vessel, and preventing blood clots.

Based on this information, Garca-Cardena's work, published this month in the journal Stem Cell Reports, has another exciting implicationit could potentially reduce, or even eliminate the need for heparin use during kidney dialysis and lung failure treatmentmaking both markedly safer.

Traditionally, patients undergoing dialysis are treated with heparin, a powerful drug, which prevents the blo
'/>"/>

Contact: B. D. Colen
bd_colen@harvard.edu
617-413-1224
Harvard University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Harvard and USC scientists show how DHA resolves inflammation
2. Harvards Wyss Institute and Sony DADC announce collaboration on Organs-on-Chips
3. Renewed Harvard-BASF initiative to advance functional materials
4. Got to go? Harvard scientists figure out how you know
5. Harvards Wyss Institute to develop smart suit that improves soldiers physical endurance
6. Researchers figure out why gold nanoparticles can penetrate cell walls
7. Finnish researchers develop quick test kit for detecting phenolic compounds in drinking water
8. BIDMC cardiovascular institute researchers will lead $4 million NIH grant to study micrornas
9. UC Davis researchers discover molecular target for the bacterial infection brucellosis
10. Researchers report a critical role for the complement system in early macular degeneration
11. Researchers study seleniums effects on horses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... life forms that have been around since the dinosaurs, ... because they can simultaneously produce other valuable products ... Engineers at Oregon State University concede that such ... not science fiction many of the needed advances ...
... tested a new technique to ensure fresh produce is free ... particles created when gases are excited by an energy source. ... research shows, some can hide from its effects in the ... and vegetables is promoted as part of a healthy lifestyle, ...
... National Heart, Lung, and Blood Institute, part of the ... to Albert Einstein College of Medicine ... study of hemoglobin toxicity that may complicate blood transfusions ... goals include making blood transfusions safer and more effective ...
Cached Biology News:Ancient diatoms could make biofuels, electronics and health food -- at the same time 2Assessing a new technique for ensuring fresh produce remains Salmonella-free 2Einstein researcher receives $10.8 million grant to study toxic blood reactions caused by hemoglobin 2
(Date:5/28/2015)... MADISON, N.J. , May 28, 2015  Quest ... provider of diagnostic information services, announced that it is ... Conference in New York.  Steve Rusckowski , the ... goals and five point strategy.  The presentation is scheduled ... Time. The presentation will be webcast live ...
(Date:5/28/2015)... , May 27, 2015 ... the addition of Jain PharmaBiotech,s new report ... to their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ... new report "Cell Therapy - Technologies, Markets ... This report describes and evaluates cell therapy technologies ... an important role in the practice of medicine. ... fashioned bone marrow transplants. Role of cells in ...
(Date:5/28/2015)... IN (PRWEB) May 28, 2015 The Academy ... National Model Aviation Day on August 15, 2015. National Model ... aviation nation-wide and to introduce model flying to the general ... 2,350 chartered clubs to participate in the celebration by hosting ... registered to host National Model Aviation Day events. View ...
Breaking Biology Technology:Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2
... , SAN DIEGO , INDIANAPOLIS and WALTHAM, Mass. ... AMLN ), Eli Lilly and Company (NYSE: LLY ) and ... and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable ... Prescription Drug User Fee Act (PDUFA) action date of October 22, ...
... , May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris ... drug development company specialized in oncology and endocrinology, today ... and Drug Administration (FDA), orphan-drug designation for AEZS-108, its ... cancer. AEZS-108 is currently in a Phase 2 trial ...
... Belgium and LUND, Sweden , May 6, 2010 , ... - TB-402 Demonstrates Superior Antithrombotic ... ThromboGenics ... from,their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant,that is ...
Cached Biology Technology:BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 2BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 3BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 4BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 5BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 6BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 7BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 8Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 2Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 3ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 2ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 3ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 4ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 5ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 6ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 7
...
... 48° Fixed Angle Polypropylene Rotor designed ... IEC Centra CL3/CL3R** and Centra-MP4/MP4R*. A ... operation. /MP4, ,EXCLUSIVE polypropylene rotor design ... be repeatedly autoclaved. Polypropylene rotors ...
... The Xcise is a powerful technology platform ... proteome analysis. High quality sample preparation ... user. , The Xcise is a powerful ... high throughput proteome analysis. It combines the ...
Request Info...
Biology Products: